Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand podcast as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

This activity offers CE credit for:

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Wednesday, November 1, 2017

Gout is the most common form of inflammatory arthritis in the United States.1 Hyperuricemia/gout in patients with CKD constitutes a significant burden for patients and society. Patients who are not managed adequately experience painful gout attacks, loss of function and productivity, and may develop long-term complications. The economic burden is also increased from patient utilization of prescription medication use, emergency room visits, and hospitalizations from gout or its serious complications.

Despite effective treatment for prevention, acute attacks, and tophi, and the availability of published treatment guidelines, there are significant gaps in treatment, patient communication, and clinical and economic outcomes for patients with hyperuricemia/gout and chronic kidney disease (CKD).

Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

Tune into this CME Outfitters On Demand activity as expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.

This activity offers CE credit for:

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, September 8, 2017

Inflammatory bowel diseases (IBD)–Crohn’s disease (CD), and ulcerative colitis (UC) –have low remission rates, indicating that conventional treatment approaches are suboptimal for patients. Treatment goals in IBD have evolving beyond symptomatic relief to sustained remission and mucosal healing to prevent continued damage, disability, and surgical intervention.

It is critical to identify patients at high risk for colectomy and plan their treatment appropriately with earlier, more aggressive utilization of immunomodulators and biologic agents; a step-down approach, in order to optimize mucosal healing and remission before permanent structural damage has occurred. Rising costs of specialty drugs are on the mind of specialty and managed care pharmacy directors, patients, and practicing physicians. When reviewing annual cost of care associated with IBD treatment, it is important to evaluate both direct costs (e.g. medication, surgery, hospitalization, lab tests) and indirect costs (e.g. quality of life, work/school productivity, absenteeism, dis

Podcast Episode

Click here for activity details, credit information, and faculty bios!

Click Here to Collect Credit

Podcast Episode

Podcast Episode

Podcast Episode MMV-062

Podcast Episode